Search All UT System Experts

Continued treatment effect of zoledronic acid dosing every 12 vs 4 weeks in women with breast cancer metastatic to bone: The OPTIMIZE-2 randomized clinical trial

Gabriel N. Hortobagyi, Catherine Van Poznak, W. Graydon Harker, William J. Gradishar, Helen Chew, Shaker R. Dakhil, Barbara B. Haley, Nicholas Sauter, Ramon Mohanlal, Ming Zheng, Allan Lipton

Research output: Contribution to journal › Article › peer-review

130 Scopus citations

Fingerprint

Dive into the research topics of 'Continued treatment effect of zoledronic acid dosing every 12 vs 4 weeks in women with breast cancer metastatic to bone: The OPTIMIZE-2 randomized clinical trial'. Together they form a unique fingerprint.

Medicine & Life Sciences